肝达康片治疗肝郁脾虚证非酒精性脂肪肝的临床观察

The liver da kang tablets in the treatment of liver stagnation and spleen deficiency syndrome clinical observation of non alcoholic fatty liver disease

目的探讨治疗非酒精性脂肪肝(NAFLD)肝郁脾虚证的方法。方法将120例NAFLD患者随机分为治疗组60例和对照组60例。治疗组给予肝达康片口服,对照组给予西药易善复(多烯磷脂酰胆碱)胶囊口服,连续服用3个月,观察2组患者治疗前后NAFLD的改善情况。结果 2组患者治疗后肝/脾CT比值均明显改善(P<0.05),且治疗组在改善肝/脾CT比值方面优于对照组(P<0.05)。治疗组在降低TC、γ-GT方面有明显作用(P<0.05),在降低LDL-C、TG、ALT、AST方面作用尤为显著(P<0.05);对照组在降低TG、TC、AST、γ-GT方面有明显作用(P<0.05),在降低ALT方面作用尤为显著(P<0.05),治疗组在降低LDL-C方面优于对照组(P<0.05)。治疗组在肝区不适、乏力方面有明显改善(P<0.05),在食欲减退、舌淡或有瘀点、脉弦或涩方面改善尤为显著(P<0.05);对照组在乏力、食欲减退方面有明显改善(P<0.05),治疗组在食欲减退、舌淡或有瘀点、脉弦或涩方面改善优于对照组(P<0.05)。治疗组总有疗效为95.0%,对照组总有效为80%,治疗组优于对照组(P<0.05)。结论口服肝达康片能改善NAFLD患者的肝/脾CT比值以及血清γ-GT、ALT、AST、TC、TG、LDLC等生化指标,也可改善患者肝区不适、食欲减退、乏力、舌淡或有瘀点、脉弦或涩等症状、体征,提高临床总体疗效,是治疗NAFLD肝郁脾虚证的有效药物。

Objective To observe the liver da kang tablets in the treatment of non alcoholic fatty liver disease （NAFLD） with liver stagnation and spleen deficiency syndrome. Method 120 cases of patients with NAFLD were randomly divided into treatment group （60 cases） and control group （60 cases）. The treatment group was given the liver Gandakang tablets orally and the control group was given western Essentiale （polyene phosphatidylchaline capsules） ,After 3 months in a row. the two groups were observed before and after treatment. Results After the treatment,The liver / spleen CT ratio of the two groups were significantly improved （P 〈 0.01 ） and the treatment group was better than the control group （ P 〈 0.05 ）. The treatment group has obvious effect in reducing TC and γ - GT（ P 〈 0.05 ）, especially in reducing LDL - C, TG, ALT, AST （P 〈 0. 05 ）. The decreasing of TG, TC, AST, γ - GT have obvious effect in the control group （ P 〈 0.05 ）, especially in reducing ALT（ P 〈 0.05 ）. The treatment group was better than the control group （ P 〈 0.05 ） in reducing LDL - C. The treatment group was significantly improved in uncomfortable of liver area and weak （ P 〈 0.05 ）. The anorexia, pale tongue, petechiae, pulse string and astringent were improved in treatment group. （ P 〈 0.05 ） The overall efficacy of the treatment group was 95.0% and, the overall effect of the control group was 80%. The treatment group was better than the control group（P 〈 0.05）. Conclusion The Liver Gandakang tablets can improve NAFLD patients with liver/spleen CT ratio and γ - GT, ALT, AST, TC,TG, LDL - C in serum. It can improve the clinical symptom. It is effective drug to treat NAFLD liver stagnation and spleen deficiency syndrome.